Literature DB >> 17337006

Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis.

Dustin Y Yoon1, Colin D Gause, James F Leckman, Harvey S Singer.   

Abstract

Frontal-subcortical abnormalities have been implicated in the pathophysiology of Tourette syndrome (TS). The goal of this study was to more extensively evaluate a possible underlying neurochemical abnormality in frontal cortex. Postmortem brain tissue from frontal and occipital regions (Brodmann's areas 4, 6, 9, 10, 11, 12, and 17) from three TS patients and three age-and sex-matched controls were analyzed by semiquantitative immunoblotting. Relative densities were measured for a variety of neurochemical markers including dopamine (D1, D2), serotonin (5HT-1A), and alpha-adrenergic (alpha-2A) receptors, the dopamine transporter (DAT), a monoamine terminal marker (vesicular monoamine transporter type 2, VMAT-2), and vesicular docking and release proteins (VAMP-2, synaptotagmin, SNAP-25, syntaxin, synaptophysin). Data from each TS sample, corrected for actin content, was expressed as a percentage value of its control. Results identified consistent increases of DAT and D2 receptor density in five of six frontal regions in all three TS subjects. D1 and alpha-2A receptor density were increased in a few frontal regions. These results support the hypothesis of a dopaminergic dysfunction in the frontal lobe and a likely role in the pathophysiology of TS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17337006     DOI: 10.1016/j.jns.2007.01.069

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  33 in total

Review 1.  Neurobiological substrates of Tourette's disorder.

Authors:  James F Leckman; Michael H Bloch; Megan E Smith; Daouia Larabi; Michelle Hampson
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

Review 2.  Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors:  Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal:  Physiol Behav       Date:  2012-07-06

Review 3.  The elusive nature of executive functions: a review of our current understanding.

Authors:  María Beatriz Jurado; Mónica Rosselli
Journal:  Neuropsychol Rev       Date:  2007-09-05       Impact factor: 7.444

4.  Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.

Authors:  Sule Tinaz; Beth A Belluscio; Patrick Malone; Jan Willem van der Veen; Mark Hallett; Silvina G Horovitz
Journal:  Hum Brain Mapp       Date:  2014-07-15       Impact factor: 5.038

5.  The Potential of Cannabinoid-Based Treatments in Tourette Syndrome.

Authors:  Bekir B Artukoglu; Michael H Bloch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

6.  Dopamine D2 Receptors Modulate Pyramidal Neurons in Mouse Medial Prefrontal Cortex through a Stimulatory G-Protein Pathway.

Authors:  Sarah E Robinson; Vikaas S Sohal
Journal:  J Neurosci       Date:  2017-09-14       Impact factor: 6.167

7.  Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats.

Authors:  Li Li; Yun-Xiao Kang; Xiao-Ming Ji; Ying-Kun Li; Shuang-Cheng Li; Xiang-Jian Zhang; Hui-Xian Cui; Ge-Ming Shi
Journal:  CNS Neurosci Ther       Date:  2017-12-06       Impact factor: 5.243

8.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

9.  Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.

Authors:  Yuko Kataoka; Paul S A Kalanithi; Heidi Grantz; Michael L Schwartz; Clifford Saper; James F Leckman; Flora M Vaccarino
Journal:  J Comp Neurol       Date:  2010-02-01       Impact factor: 3.215

10.  Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders.

Authors:  V Roessner; T Banaschewski; A Fillmer-Otte; A Becker; B Albrecht; H Uebel; J Sergeant; R Tannock; A Rothenberger
Journal:  J Neural Transm (Vienna)       Date:  2007-09-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.